logo
  

Equity Residential Profit Rises; Lifts FY Guidance

Equity Residential (EQR), a real estate investment trust that develops multifamily properties, on Tuesday reported second-quarter funds from operations of $341.3 million or $0.90 per share compared with $290.8 million or $0.77 per share last year.

Excluding items, normalized FFO for the quarter was $0.85 per share compared with $0.78 per share a year ago.

Analysts polled by Thomson Reuters estimated FFO of $0.85 per share for the quarter. Analysts' estimates typically exclude special items.

Net earnings for the quarter were $285.6 million or $0.78 per share compared with $111.7 million or $0.31 per share last year.

Revenues for the quarter were $679.1 million compared with $652.6 million in the prior year.

Analysts estimated revenues of $676.7 million for the quarter.

Same store revenue, which includes 97,580 apartment unit, increased 4.9% in the quarter, the company said.

"Fundamental apartment demand in the coastal, high density urban markets targeted by Equity Residential continues to benefit significantly from extremely favorable demographics, steady improvement in employment and changing lifestyles," said David Neithercut, Equity Residential's CEO.

For the third quarter, the company expects FFO of $0.86 to $0.90 per share and normalized FFO of $0.85 to $0.89 per share. Analysts expect FFO of $0.88 per share.

For the full year 2015, the company now expects FFO of $3.42 to 3.48 per share and normalized FFO of $3.39 to $3.45 per share. Earlier it expected expect FFO of $3.37 to 3.45 per share.

Analysts expect FFO of $3.43 per share.

The company now expects 2015 same store revenue to increase 4.75% to 5%, from prior guidance of 4.3% to 4.7%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT